NCT06439836 2026-03-18Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior ImmunotherapyNational Cancer Institute (NCI)Phase 1 Recruiting27 enrolled